Jaguar Health

142 articles with Jaguar Health

• Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th

  4/6/2022

  Jaguar Health, Inc. today announced that the company is hosting a dinner and tableside discussion for U.S. veterinary oncologists in Puerto Vallarta, Mexico from 5:30 PM - 10:00 PM on Tuesday, April 12, 2022, the final day of the Veterinary Cancer Society (VCS) Mid-Year Conference.

• Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer

  4/5/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar.

• Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets

  3/31/2022

  Jaguar Health, Inc. announced that the company has entered an agreement with Quadri Pharmaceuticals Store LLC that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates.

• Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast

  3/14/2022

  Jaguar Health, Inc. announced that the recording of the company's March 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended December 31, 2021 can be accessed by clicking here.

• Jaguar Health Provides Company Updates and Reports 2021 Financials

  3/11/2022

  Jaguar Health, Inc. provided company updates and reported consolidated financial results for the year ended December 31, 2021.

• Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates

  3/7/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.

• Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas

  3/1/2022

  Jaguar Health, Inc. announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea in dogs at the Mandalay Bay Resort and Casino in Las Vegas on Sunday, March 6, 2022 from 5:30 PM - 7:30 PM Pacific Time during the Western Veterinary Conference, which is being held at the same location.

• Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs

  2/16/2022

  Jaguar Health, Inc. announced that it has submitted a request to the U.S. Food and Drug Administration's Center for Veterinary Medicine for Minor Use/Minor Species designation for the company's oral plant-based drug candidate Canalevia™ for treatment of exercise-induced diarrhea in dogs.

• Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

  2/15/2022

  Jaguar Health today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

• Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs

  2/10/2022

  Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that it has completed filing of the final major regulatory section with the U.S. Food and Drug Administration's Center for Veterinary Medicine to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea in dogs.

• Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)

  2/1/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Pharmaceuticals, the company's wholly owned subsidiary, today announced the completion of a third-party, investigator-initiated preclinical enterocyte.

• Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics

  1/24/2022

  Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics.

• Jaguar Health Provides Corporate Update and Outlines 2022 Milestones

  1/13/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) today provided a corporate update and outlined expected 2022 milestones.

• Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida

  1/12/2022

  Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea in dogs on Sunday, January 16 from 6 p.m. - 8 p.m.

• Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

  1/4/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced the launch of Canalevia (crofelemer delayed-release tablets).

• Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs

  12/22/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today shared the following quote from the press release the U.S. Food and Drug Administration (FDA) issued December 21, 2021.

• Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs

  12/20/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics S.p.A. effective December 17, 2021.

• Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea

  12/10/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals today announced the third-party presentation of findings from the investigator-initiated HALT-D trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.

• Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)

  12/6/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting a closed satellite event on December 9, 2021 at SABCS in San Antonio, Texas.

• Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients

  11/19/2021

  Jaguar Health, Inc. announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.